Cargando…
Gap between pediatric and adult approvals of molecular targeted drugs
To clarify the approval status of molecular targeted antineoplastic drugs in the United States (U.S.), the European Union (E.U.), and Japan (JP), we checked the status of pediatric indications according to the package insert of each drug. A total of 103 drugs were approved for adult patients in at l...
Autores principales: | Nishiwaki, Satoshi, Ando, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555892/ https://www.ncbi.nlm.nih.gov/pubmed/33051474 http://dx.doi.org/10.1038/s41598-020-73028-w |
Ejemplares similares
-
Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan
por: Nishiwaki, Satoshi, et al.
Publicado: (2019) -
I-ACT for Children: helping close the gap in drug approval for adults and children
por: Coppes, Max J., et al.
Publicado: (2022) -
COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective
por: Nishiwaki, Satoshi, et al.
Publicado: (2021) -
Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
por: Lin, Hui-Heng, et al.
Publicado: (2017) -
Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2021)